Aptevo Therapeutics Inc. income statement

In fiscal 2022, Aptevo Therapeutics Inc. reported revenue of $3.1m, down 74.7% on the year before, operating income of −$28.6m (a -919.7% margin) and net income of $8.0m, or $1.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aptevo Therapeutics Inc.: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	34	10	15	23	32	4	12	3
Cost of revenue	—	—	—	11	20	—	—	—
Gross profit	—	—	—	12	12	—	—	—
Research and development	35	29	29	35	25	18	19	18
Selling, general and administrative	43	36	35	28	25	—	—	—
General and administrative	—	—	—	—	—	14	15	14
Operating income	−61	−139	−54	−52	−41	−27	−21	−29
Income before tax	−61	−140	−56	−54	−43	−31	−29	7
Income tax	−2	−20	−23	—	—	—	—	—
Net income	−59	−112	7	−54	−40	−18	−28	8
Diluted EPS	−$14767.20	−$5.55	$0.33	−$2.39	−$13.86	−$5.23	−$6.07	$1.57
Diluted shares (average)	—	—	—	—	—	—	—	—
EBITDA	−58	−135	−51	−49	−39	−26	−20	−28

US$ millions unless shown otherwise. Fiscal quarters.

Aptevo Therapeutics Inc.: income statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	2	3	3	4	3	0	0	0
Research and development	5	5	4	5	5	4	4	5
General and administrative	4	4	3	3	4	4	3	3
Operating income	−7	−6	−5	−4	−6	−8	−8	−8
Net income	−7	−8	−7	−6	−8	28	−8	−5
Diluted EPS	−$1.64	−$1.75	−$1.43	−$1.27	−$1.55	$5.58	−$1.50	−$0.95
EBITDA	−7	−5	−4	−4	−5	−7	−8	−8

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aptevo Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aptevo Therapeutics Inc.